Viking Therapeutics up 1% in extended trading after completing enrollment in obesity drug late-stage trial

VKTX Viking Therapeutics Inc

$27.37 +7.46%

View chart & analysis →

1. 1Viking Therapeutics (VKTX) shares rose 1% in Wednesday's extended trading as the company updated progress on its obesity drug program alongside its second-quarter results.
2. 2Two large late-stage trials of injectable VK2735 have completed enrollment and are proceeding on schedule, while the late-stage trial of the oral formulation is expected to begin in the fourth quarter of 2026.
3. 3As a clinical-stage company with no approved drugs, Viking posted a second-quarter net loss of $128 million and said its $502 million in cash as of the end of June is sufficient to complete the Phase 3 trials.

Source Stocktwits +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →